Results 61 to 70 of about 20,735 (212)
Infection and Drug Resistance, 2022 Blanka Wolszczak Biedrzycka,1,2 Anna Bieńkowska,1,2 Elwira Smolińska-Fijołek,3 Grzegorz Biedrzycki,4 Justyna Dorf5 1Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn ...
Wolszczak Biedrzycka B +4 more
doaj
JHEP Reports, 2023 Background & Aims: Millions of people worldwide are infected chronically with HBV, which results in significant morbidity and mortality. Therapeutic vaccination is a strategy that aims to induce functional cure by restoring cellular immunity to HBV ...
Tamsin Cargill +14 more
doaj +1 more source
LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
Neurological Research and Practice, 2022 AbstractA 71-year-old male patient was diagnosed with LGI1 encephalopathy 4 weeks following a first ChAdOx1 nCov-19 vaccination. Extensive work-up including analysis of CSF and PET examination did not reveal a tangible cause so that a vaccine-associated encephalopathy was considered as differential diagnosis.
Tamara Garibashvili +1 more
openaire +3 more sources
Vaccines, 2021 To establish a successful anti-SARS-CoV-2 vaccination strategy, it is necessary to take possible tradeoffs into account. We conducted a survey on vaccinated healthcare workers (HCWs) inthree referral teaching hospitals in the Republic of Korea.
Tark Kim +7 more
doaj +1 more source
A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial [PDF]
, 2021 Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals.
Azar, Sasha R. +22 more
core +1 more source
A case of Thrombotic Thrombocytopenic Purpura following the AstraZeneca Vaccine
Journal of Ardabil University of Medical Sciences, 2022 A severe acute respiratory syndrome caused by coronavirus 2 infection (COVID-19)was identified in December 2019 and caused a massive pandemic that claimed millions of lives worldwide.
Effat Iranijam +3 more
doaj
The Lancet Regional Health. Europe, 2021 Summary: Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we ...
Peter Nordström +2 more
doaj +1 more source
BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
Frontiers in Medicine, 2021 Background: Vaccination against SARS-CoV-2 is important for reducing hospitalization and mortalities. Both Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccines are used in Saudi Arabia and in many parts of the world.
Ahmed N. Alghamdi +4 more
doaj +1 more source
Risk of myocarditis following sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex [PDF]
, 2022 Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.
Channon, Keith M +13 more
core +1 more source
Serious adverse events following immunization after ChAdOx1 nCov-19 vaccination in India: a single center experience [PDF]
, 2021 Letter to ...
Libby Pushparajan +2 more
core +2 more sources